Home > Boards > US OTC > Cannabis >

Skye Bioscience Inc. (SKYE)

SKYE RSS Feed
Add SKYE Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/30/2021 4:09:31 AM - Followers: 134 - Board type: Free - Posts Today: 0

THCVHSCloseOpen

Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).

Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.

One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.

At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.

THCVHS for the treatment of glaucoma

Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.

According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.

Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.

 

In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.

Additionally, it has been demonstrated:

  • Skye’s THCVHS formulation enables it to better enter various compartments of the eye vs natural THC
    Its formulation lowers IOP better than leading current prescribed drugs in animal models
    THCVHS or its metabolite (THC) is not detectable in the plasma or brain tissue after topical administration to the eye
    THC in an ex vivo model demonstrated lowering of IOP and the reduction of biomarkers related to fibrosis, inflammation, and vasodilation, supporting a multimodal mechanism of action.
 

CBDVHS
CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical modelsPreliminary data suggest potential analgesic, anti-inflammatory, anti-fibrotic, anti-infective and anti-seizure activity of CBDVHS opening the door to multiple therapeutic applications. We are actively conducting additional preclinical studies to help determine and prioritize a well we defined development plan for CBDVHS.


Team

 

Our Mission

We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.

Our Vision

Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.

Our Values

Science First
The foundation of Skye Bioscience.

Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.

Product-led
Commercial differentiated applications to provide therapeutic benefits.

Impact driven
Change makers. Platform solutions that can extend beyond a single disease.

Management

Punt Dhillon

CEO

Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

+Read More

Tu Diep,MSc

Senior Vice President, Development 

Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.

+Read More

Richard Janney 

Principal Accounting Officer 

Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.

+Read More

Tom Kim,Esq

General Counsel & Director of IP 

Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.

+Read More

Karam Takhar 

Vice President, Corporate Development & Investor Relations

Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.

+Read More

Board of Directors

Punit Dhillon

Chair

Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.

+Read More

Jim Heppell,LLB

Director

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.

+Read More

Margaret Dalesandro,PhD

Director

Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development. 

+Read More

Scientific Advisory Board 

Eduardo Muñoz,MD, PhD

Scientific Advisor

Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.

+Read More

Giovanni Appendino,PhD

Scientific Advisor 

Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation .. 

+Read More

Clinical Advisory Board 

Jeffrey Goldberg,MD, PhD

Ophthalmology Clinical Advisor 

Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.

+Read More

Louis Pasquale,MD, FARVO

Ophthalmology Clinical Advisor 

Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.

+Read More

Robert Ritch,MD

Ophthalmology Clinical Advisor 

Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.

+Read More
SKYE
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#6234   We should start moving in december...finaly Dutchpaul1 11/30/21 04:09:31 AM
#6233   Yikes.... https://www.nsnews.com/bc-news/time-ticking-for-vancouver-man-charged frozenspokes 11/23/21 05:01:44 PM
#6232   Is it just me or is chart looking bobbleheadtwin 11/01/21 11:27:25 AM
#6231   no i did not.. i sold at 0.07 Chefboy69 10/25/21 09:00:16 PM
#6230   You sold and took a loss on the Romes14 10/25/21 12:31:16 PM
#6229   sold and took a loss here. Chefboy69 10/25/21 09:58:02 AM
#6228   Skye recently updated its clinical development strategy and mmjbuyer 10/21/21 06:13:36 PM
#6227   Skye Bioscience Sponsored Research Presented at American Association lolroflmao 10/21/21 10:42:34 AM
#6226   Yep when Company starts issuing shares to fund N.C.LUCKY(7) 10/18/21 01:56:48 PM
#6225   they just created another 80M shares w warrants mmjbuyer 10/14/21 10:59:26 AM
#6224   Over a million on the ask?? Scout72 10/14/21 09:37:56 AM
#6222   Punit way to driver shareholder value. This will mmjbuyer 10/12/21 08:58:25 PM
#6221   This what happens when you have press release Scout72 10/12/21 02:39:47 PM
#6220   Published 39 mins ago N.C.LUCKY(7) 09/24/21 01:51:30 PM
#6219   CNBC FAST MONEY pot stock are big winners N.C.LUCKY(7) 09/24/21 01:30:01 AM
#6218   Awesome News Here.. The U.S. House of Representatives N.C.LUCKY(7) 09/22/21 12:53:54 AM
#6217   BOOM bobbleheadtwin 09/21/21 09:16:43 AM
#6216   $SKYE Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts bobbleheadtwin 09/21/21 09:16:20 AM
#6215   NEWS bobbleheadtwin 09/21/21 09:08:51 AM
#6214   News 9-14-2021 Change in Director of Principal officer... https://m.marketscreener.com/quote/stock/S N.C.LUCKY(7) 09/17/21 04:21:04 PM
#6213   https://m.marketscreener.com/quote/stock/SKYE-BIOSCIENCE-INC-111314073/news/SKYE N.C.LUCKY(7) 09/17/21 04:21:03 PM
#6212   Time to Buy Pot Stocks! N.C.LUCKY(7) 09/04/21 03:22:28 AM
#6211   Positive News for SKYE: https://finance.yahoo.com/news/skye-bioscience-completes N.C.LUCKY(7) 08/10/21 10:34:38 AM
#6210   SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) Scout72 08/10/21 09:59:51 AM
#6208   why the volume surge? And the bump up? Chefboy69 07/27/21 10:44:24 AM
#6207   Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. Southern Gal 07/26/21 08:39:06 AM
#6206   And? jlee3 07/21/21 11:36:00 PM
#6205   https://www.youtube.com/watch?v=QX5UI4q4P6Y Southern Gal 07/21/21 02:08:55 PM
#6204   https://d1io3yog0oux5.cloudfront.net/_5adeb041b362f0c3b02efb74eca84ff2/skyebiosc Southern Gal 07/18/21 10:40:43 AM
#6203   #SKYE: WHAT DO WE HAVE HERE...:-)? $0.17 captainscotty 07/10/21 07:29:34 AM
#6202   SKYE PREFORMING BEAUTIFUL LOOKING GREAT HERE. .. N.C.LUCKY(7) 06/16/21 06:52:45 PM
#6201   Great time to buy imo Fishazo 06/09/21 05:30:59 PM
#6200   I am hoping for this to go back jamcneel 06/04/21 11:04:58 AM
#6199   Skye good informative video bobbleheadtwin 06/03/21 05:43:27 AM
#6198   This News was Awesome looking Foward... https://finance.yahoo.com/news/skye-bios N.C.LUCKY(7) 06/02/21 11:24:53 PM
#6197   Undervalued... In the whole time I have N.C.LUCKY(7) 06/02/21 11:19:29 PM
#6196   I got an "alert" two days ago from Blue Man 06/02/21 10:11:06 PM
#6195   why the sudden upswing? are there any news Chefboy69 06/02/21 09:42:30 PM
#6194   LITTLE BLUE SKYE BREAK OUT MUSIC... KICK START N.C.LUCKY(7) 06/02/21 02:34:09 PM
#6193   NMUS->EMBI->SKYE-> Moon let's goo!!!! Jdanger 2 06/02/21 02:18:47 PM
#6192   NEW 52 WEEK HIGH bobbleheadtwin 06/02/21 01:44:09 PM
#6191   JUST BEAUTIFUL Southern Gal 06/02/21 10:09:36 AM
#6190   The 1 analysts offering 12-month price forecasts for Dutchpaul1 06/01/21 09:48:43 AM
#6189   Today’s upgrade from Stockinvest: Southern Gal 05/29/21 09:56:26 AM
#6188   Closed up 26.4% on 4,200,000 shares Southern Gal 05/28/21 04:01:22 PM
#6187   Something is up. Bring the news Scout72 05/28/21 03:48:18 PM
#6186   Volume and movement Southern Gal 05/28/21 03:36:47 PM
#6185   NICE CLOSE TODAY FOR SKYE.. GOOD VOLUME ALSO.. N.C.LUCKY(7) 05/18/21 05:04:40 PM
#6184   BOOM....If we can get some new eyeballs on frozenspokes 05/17/21 09:08:15 AM
#6183   I feel you... Dutch Paul... Market makers N.C.LUCKY(7) 05/14/21 02:54:22 PM
PostSubject
Consent Preferences